We have initiated a tumor-infiltrating lymphocyte (TIL) therapy program that has now treated over 70 metastatic melanoma patients with an ongoing 45-50% clinical response rate. In parallel, we are performing correlative biomarker studies to identify specific lymphocyte subsets within infused TIL associated with clinical responses. In a recent FACS-based phenotypic screen on over 31 treated patients, we found that a subset of differentiated CD3+CD8+CD45RA-CD62L-CD27-effector-memory (EM) cells expressing B- and T- lymphocyte attenuator (BTLA) stood out to be most strongly associated with clinical response. Other EM markers, such as CD27, CD28, CD25, and PD-1 were not predictive. Although BTLA is classically defined as a negative co-stimulatory molecule on activated T cells, recent data suggests it is also a new marker in the CD8+ CTL differentiation program and that melanoma-specific CD8+ T cells expressing BTLA have a less differentiated, more polyfunctional phenotype in vivo. Preliminary data in our lab has also found that sorted CD8+BTLA+ melanoma TIL have a high proliferative response to IL-2, while their BTLA- counterparts were hyporesponsive and prone to apoptosis. In addition, we have found that once BTLA is lost on T cells, it cannot be re-expressed. These observations have led us to hypothesize that the BTLA+CD8+ TIL subset represents a less differentiated, polyfunctional subset whose persistence in vivo results in enhanced responsiveness to adoptive T cell therapy in melanoma. To address this hypothesis, we propose to further unravel the role of this CD8+BTLA+ melanoma TIL subset in adoptive cell therapy.
In Aim #1, we will perform a series of in vitro assays on sorted BTLA+ and BTLA- TIL studying their EM properties (proliferation, survival, response to TCR and cytokine stimulation) and their anti-tumor effector activity.
In Aim #2, using high-throughput TCR V? CDR3 region sequencing, we will track the long-term fate of T-cell clones in vivo from the CD8+BTLA+ or CD8+BTLA- sub-populations infused into patients.
In Aim #3, we will focus in more on the mechanistic role of the CD8+BTLA+ versus the BTLA- subset in a set of adoptive transfer experiments in NOD-SCID x ?c-/- (NSG) mice, where we will study the relative persistence, tumor infiltration, and anti-tumor effector function of these subsets. These experiments will also test whether blockade of BTLA, using anti-BTLA antibodies, enhances tumor control to address a corollary hypothesis that although BTLA is a marker for more highly functional T cells, it still serves as a negative costimulatory molecule through its interaction with the herpes virus entry mediator (HVEM) expressed on melanoma cells. This project is innovative as it will characterize a novel biomarker in adoptive T-cell therapy whose loss may identify a key turning point in CD8+ CTL differentiation towards a senescent state.

Public Health Relevance

We have developed a powerful new way to fight metastatic melanoma, an otherwise lethal disease, by harnessing the power of the immune system using a new therapy called adoptive T-cell therapy. Adoptive T-cell therapy entails the infusion of highly reactive immune cells (T cells) into melanoma patients and has resulted in major shrinkage of tumors in up to 50% of patients, with some patients enjoying complete eradication of their cancer. During the current phase II clinical trial at MD Anderson, our group discovered that the presence of specific subset of CD8+ T lymphocytes expressing B-and-T lymphocyte attenuator (BTLA) in the infusion product positively correlated with clinical response to ACT. In this project we will begin to characterize this novel subset of expanded CD8+ TIL expressing the marker BTLA associated with the induction of tumor regression during TIL adoptive cell therapy. This BTLA+ subset may not only be an optimal sub-population to transfer in order to further improve clinical response rates to TIL therapy, but may also be a novel sub-stage in the differentiation program of CD8+ CTL just before a senescent-prone BTLA- phenotype emerges.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-B (M1))
Program Officer
Song, Min-Kyung H
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
Internal Medicine/Medicine
Other Domestic Higher Education
United States
Zip Code